MODN Stock UPDATES Model N Inc. Common Stock (MODN) 9.69 10/30/2014

New Post Public Reply Private Reply Replies (0) Message Board

Oct 30, 2014 at 4:26 AM

Model N Inc. Common Stock (MODN) 9.69 $MODN

Model N's TARP offers cloud price quote solution
M2 - Tue Oct 14, 10:39AM CDT
Model N, Inc. (NYSE: MODN) said that its CPQ Total AppRust Replacement Program liberates companies from spreadhseets and antiquated CPQ software by risk-free migration to its Revvy CPQ cloud solution.
MODN: 9.69 (-0.06), CRM: 60.97 (-0.56)

Model N Expands Revvy Configure, Price Quote Solution to Medical Technology Market With Integrated Analytics
Marketwired - Tue Oct 14, 7:07AM CDT
Dreamforce 2014 -- Model N, Inc. (NYSE: MODN), a leading revenue management solutions provider to the life science and technology industries, announced today its next-generation Revvy CPQ (Configure, Price, Quote) for medical technology manufacturers.
MODN: 9.69 (-0.06), CRM: 60.97 (-0.56)

Model N Announces Date of Fourth Quarter and Fiscal Year 2014 Financial Results
Business Wire - Mon Oct 13, 3:05PM CDT
Model N, Inc. (NYSE: MODN), the leader in Revenue Management Cloud solutions to the life science and technology industries, plans to announce financial results for the fourth quarter and fiscal year 2014 after market close on Monday, November 10, 2014. The company also will host a conference call that day at 2:00 p.m. PT / 5:00 p.m. ET to review its financial results and business outlook.
MODN: 9.69 (-0.06)

Model N Extends Revenue Management Leadership With Expansion of Its Revvy Platform
Marketwired - Mon Oct 13, 7:32AM CDT
Dreamforce 2014 -- Model N, Inc. (NYSE: MODN), the leading revenue management solutions provider, announced today that it will be showcasing multiple applications on Revvy, Model N's multi-tenant SaaS platform for revenue management.
MODN: 9.69 (-0.06)

Model N Drives Sales Effectiveness for Semiconductor and Component Manufacturers With the Revvy Sales Application Suite
Marketwired - Mon Oct 13, 7:32AM CDT
Model N, Inc. (NYSE: MODN), the leading revenue management solutions provider to the life science and technology industries, today announced its vertical cloud solution.
MODN: 9.69 (-0.06), CRM: 60.97 (-0.56)

Model N Announces CPQ TARP
Marketwired - Mon Oct 13, 7:32AM CDT
Model N, Inc. (NYSE: MODN), the provider of Revvy CPQ, a world-class CPQ solution preferred by sales users 4-to-1(1), announced today its CPQ Total AppRust Replacement Program (TARP) liberating companies from spreadhseets and antiquated CPQ software by risk-free migration to its powerful Revvy CPQ cloud solution. Designed to cut through cluttered sales processes, Model N Revvy CPQ provides an easy-to-use app for Salesforce.com customers, enabling them to maximize revenues, maximize sell time and maximize the number of new opportunities.
MODN: 9.69 (-0.06), CRM: 60.97 (-0.56)

Model N Joins Analytics Cloud Ecosystem to Empower Salespeople to Maximize Revenue
Marketwired - Mon Oct 13, 7:32AM CDT
Dreamforce 2014 -- Model N, Inc. (NYSE: MODN), a leading revenue management solutions provider to the life science and technology industries, today announced it has joined the Salesforce Analytics Cloud ecosystem to empower sales reps with powerful revenue management analytics that puts them in control of and greatly accelerates the sales cycles.
MODN: 9.69 (-0.06)

Zerto Names Mark Leslie to Board Of Directors
PR Newswire - Wed Sep 10, 8:45AM CDT
Zerto today announced the appointment of Mark Leslie to its Board of Directors. Leslie, widely known as a successful high technology entrepreneur in Silicon Valley and board member at numerous top storage and infrastructure startups, is the managing director of Leslie Ventures, a private investment company based in Silicon Valley. As founding Chairman and CEO of VERITAS Software, Leslie drove the company's global deployment and growth from 12 to 6,000 employees, and from a revenue base of $95,000 per year to $1.5 billion per year.
MODN: 9.69 (-0.06), VRTS: 174.98 (+4.95)

Model N Gold Sponsor at Key Pharmaceutical, MedTech Conferences in September
PRWeb - Mon Sep 08, 11:09PM CDT
Model N, Inc. (NYSE: MODN), the leading Revenue Management solutions provider to the life science and technology industries, announced today that it will be sponsoring two prominent life sciences events, The Institute for International Research 19th Annual Summit on the Medicaid Drug Rebate Program (MDRP) on September 15-17 in Chicago and the 2nd Annual Medical Device Strategic Pricing Conference on September 15-16 in Atlanta, as well as a FierceHealth Webinar "New Regulatory Compliance - Strategies for Pharma Leaders" on September 25 at 11a PT/2p ET.
MODN: 9.69 (-0.06)

Model N Welcomes David Bonnette to its Board of Directors
PRWeb - Tue Sep 02, 2:11AM CDT
Model N, Inc. (NYSE: MODN), the leading revenue management solutions provider to the life science and technology industries, announced today that David Bonnette, Chief Executive Officer of Lanyon, has been appointed to its Board of Directors, effective August 29th, 2014. Bonnette will replace Jay Larson who is resigning from the board.
MODN: 9.69 (-0.06)

Model N to Present at Deutsche Bank Technology Conference
Business Wire - Wed Aug 27, 3:05PM CDT
Model N, Inc. (NYSE: MODN), the leading revenue management solutions provider to the life science and technology industries, today announced that Zack Rinat, Chairman, Founder and Chief Executive Officer and Mark Tisdel, Senior Vice President and Chief Financial Officer, will be presenting at the 2014 Deutsche Bank Technology Conference in Las Vegas, NV.
MODN: 9.69 (-0.06), DB: 31.20 (-1.28)

Model N Launches Model N Express as the Enterprise Grade SaaS Offering for the Midmarket
PRWeb - Wed Aug 20, 2:23AM CDT
Model N, Inc. (NYSE: MODN), the leading revenue management solutions provider to the life science and technology industries, announced today that it has launched Model N Express, a comprehensive, pre-configured SaaS revenue management solution built on best practices and optimized for mid-size Pharma and MedTech companies.
MODN: 9.69 (-0.06)

Model N to Present at Pacific Crest Global Technology Leadership Forum
Business Wire - Thu Aug 07, 3:05PM CDT
Model N, Inc. (NYSE: MODN), the leading revenue management solutions provider to the life science and technology industries, today announced that Mark Tisdel, Senior Vice President and Chief Financial Officer, will present at the 2014 Pacific Crest Global Technology Leadership Forum in Vail, CO.
MODN: 9.69 (-0.06)

Model N Announces Third Quarter Fiscal 2014 Financial Results
Business Wire - Tue Aug 05, 3:06PM CDT
Model N, Inc., (NYSE: MODN), the leading revenue management solutions provider to the life science and technology industries, today announced financial results for the third quarter of fiscal 2014, which ended June 30, 2014.
MODN: 9.69 (-0.06)

Commit To Buy Model N At $8, Earn 15.7% Annualized Using Options
StockOptionsChannel.com - Thu Jul 31, 10:29AM CDT
Investors eyeing a purchase of Model N, Inc stock, but cautious about paying the going market price of $9.67/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in...
MODN: 9.69 (-0.06)

Ranbaxy Moves to Model N Revenue Management for Unified, Global View of Revenue Life Cycle
PRWeb - Tue Jul 15, 2:18AM CDT
Model N, Inc. (NYSE: MODN), the leading revenue management solutions provider to the life science and technology industries, and Ranbaxy Pharmaceuticals Inc. of Jacksonville, Florida announced today that Ranbaxy has selected Model N's revenue management suite to improve financial controls and gain a more unified global view of its revenue lifecycle. Ranbaxy will be replacing its existing legacy point solutions with Model N's global end-to-end solution to support their strategic direction as the company responds to tremendous consumer demand for its affordable generic medications.
MODN: 9.69 (-0.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....